Health
globalreutersSeptember 27, 20241 Mins read
FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades
globalreutersSeptember 27, 20241 Mins read 
Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics.
The post FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades appeared first on MedCity News.
Related Articles
Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?
Cost effectiveness analyses (CEA) aim to examine how a new health technologies...
5 Interesting Companies I Saw at HLTH
I met a mix of biotech and healthtech companies at HLTH affecting...
Patty Hayward, TalkDesk
Patty Hayward is GM of Healthcare and Life Sciences at TalkDesk. TalkDesk...
How chatbots are enhancing patient care
Consumers have come to expect options when communicating with the companies they...
Leave a comment